EP1196162A4 - Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same - Google Patents

Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same

Info

Publication number
EP1196162A4
EP1196162A4 EP00942520A EP00942520A EP1196162A4 EP 1196162 A4 EP1196162 A4 EP 1196162A4 EP 00942520 A EP00942520 A EP 00942520A EP 00942520 A EP00942520 A EP 00942520A EP 1196162 A4 EP1196162 A4 EP 1196162A4
Authority
EP
European Patent Office
Prior art keywords
medicine
same
matrix metalloproteinases
effective composition
procyanidin oligomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00942520A
Other languages
German (de)
French (fr)
Other versions
EP1196162A1 (en
Inventor
Sang-Nyun Kim
Ho-Jeong Ahn
Sang-Ki Park
Moon-Moo Kim
Jung-Hun Kim
Hak-Mo Lee
Hyoung-Kook Park
Hye-Sung Cho
Seung-Young Jeoung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG H&H Co Ltd
Original Assignee
LG Household and Health Care Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Household and Health Care Ltd filed Critical LG Household and Health Care Ltd
Publication of EP1196162A1 publication Critical patent/EP1196162A1/en
Publication of EP1196162A4 publication Critical patent/EP1196162A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EP00942520A 1999-07-16 2000-07-14 Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same Withdrawn EP1196162A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-1999-0028877A KR100509119B1 (en) 1999-07-16 1999-07-16 Medicine comprising procyanidine as an effective agent
KR9928877 1999-07-16
PCT/KR2000/000769 WO2001005397A1 (en) 1999-07-16 2000-07-14 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same

Publications (2)

Publication Number Publication Date
EP1196162A1 EP1196162A1 (en) 2002-04-17
EP1196162A4 true EP1196162A4 (en) 2003-06-18

Family

ID=19602329

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00942520A Withdrawn EP1196162A4 (en) 1999-07-16 2000-07-14 Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same

Country Status (9)

Country Link
EP (1) EP1196162A4 (en)
JP (1) JP2003504402A (en)
KR (1) KR100509119B1 (en)
CN (1) CN1364082A (en)
AU (1) AU5713000A (en)
BR (1) BR0012431A (en)
CA (1) CA2379489A1 (en)
MX (1) MXPA02000598A (en)
WO (1) WO2001005397A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1256335A1 (en) * 2001-05-10 2002-11-13 Cognis France S.A. Use of procyanidine oligomers
KR100439627B1 (en) * 2001-06-18 2004-07-12 주식회사 엘지생활건강 Composition for preventing and treating of skin wrinkles
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
KR100441131B1 (en) * 2001-08-22 2004-07-21 애경산업(주) Cosmetic compositons for acne skin containing natural fragrant oil
KR100441565B1 (en) * 2001-09-27 2004-07-23 이형주 Extracts of buckwheat and/or buchwheat chaff with anti-inflammatory effects and food composition comprising of the same
KR20030032359A (en) * 2001-10-17 2003-04-26 주식회사 엘지생활건강 Oral pharmaceutical composition for curing periodontal disease comprising ulmus cortex extract
KR100531472B1 (en) 2002-08-09 2005-11-28 주식회사 이롬 Cosmetic composition comprising extract of Rosa multiflora with antioxdative activity and preparation method of the extract
KR20070097581A (en) * 2004-03-26 2007-10-04 아사히비루 가부시키가이샤 A protectant of periodontal membranes
EP1616551A1 (en) * 2004-07-13 2006-01-18 L'oreal Cosmetic treatment for preventing or delaying the signs of skin ageing
FR2873026B1 (en) * 2004-07-13 2009-10-30 Oreal COSMETIC PROCESSING METHOD FOR PREVENTING OR DELAYING THE SIGNS OF AGING
CA2599295C (en) * 2005-02-25 2014-10-14 Nagasaki University Method of producing proanthocyanidin oligomer
US20060194746A1 (en) * 2005-02-28 2006-08-31 Peter Rohdewald Method and composition to inhibit infections with Helicobacter pylori by intake of procyanidins from type B and C
KR100687522B1 (en) * 2005-05-28 2007-02-27 한국화학연구원 Therapeutic agent for antiinflammatory disease induced by pge2 activity containing 2,2-dimethyl-3-ester-4-alkoxy-6-alkyl amino benzopyrane derivatives as an effective ingredient
US20060293258A1 (en) * 2005-06-23 2006-12-28 Peter Rohdewald Method and composition to treat skin ulcers
JP4942953B2 (en) * 2005-06-30 2012-05-30 サントリーホールディングス株式会社 Analysis method of procyanidins
ES2546864T3 (en) * 2008-03-05 2015-09-29 Council Of Scientific & Industrial Research New compounds of flavonol, a fraction / bioactive extract of Ulmus wallichiana and its compounds for the prevention or treatment of disorders related to bone health
JP5602416B2 (en) * 2009-11-13 2014-10-08 日油株式会社 Hyaluronidase activity inhibitor
KR101438517B1 (en) * 2012-06-13 2014-09-17 경희대학교 산학협력단 Composition for prevention, improvement and treatment of acne including flavan-3-ol multimer, derivative thereof or acceptable salt thereof as an active ingredient
ES2699247T3 (en) * 2012-08-07 2019-02-08 Indus Biotech Private Ltd A management method for diabetic foot ulcers, pressure ulcers, venous leg ulcers and associated complications
US20140179774A1 (en) * 2012-12-26 2014-06-26 Industrial Technology Research Institute Methods for inhibition of shc-1/p66 to combat aging-related diseases
KR101760691B1 (en) * 2014-09-26 2017-07-24 연천군 Health functional food for preventing pancreatic adenocarcinoma
CN105998037A (en) * 2016-06-16 2016-10-12 汕头大学 Application of doxycycline to preparation of medicine for treating or preventing aging diseases
KR102074067B1 (en) * 2018-05-02 2020-02-06 주식회사 마크로케어 Capsule comprising salvianolic acid and the use of the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672800A1 (en) * 1991-02-15 1992-08-21 Dolisos Lab NOVEL THERAPEUTIC USE OF PYCNOGENOLS FOR THE PREPARATION OF MEDICAMENTS WITH ANTI-INFLAMMATORY ACTIVITY.
WO1993024106A1 (en) * 1992-05-27 1993-12-09 L'oreal Composition comprising a proanthocyanidin oligomer encapsulated in a liposome
EP0815857A1 (en) * 1995-12-26 1998-01-07 Suntory Limited Antiobestic agent containing procyanidin as the active ingredient
FR2770228A1 (en) * 1997-10-27 1999-04-30 Greentech Sa Proanthocyanidine oligomer concentrates obtained by fermenting Schinopsis lorenzii extract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219732B (en) * 1988-06-28 1990-05-24 Tecnofarmaci Spa PROCYANIDOLIC OLIGOMERIC FRACTIONS, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5646178A (en) * 1992-10-09 1997-07-08 Jlb, Inc. Cranberry extract and biologically active compounds derived therefrom
US5554645A (en) * 1994-10-03 1996-09-10 Mars, Incorporated Antineoplastic cocoa extracts and methods for making and using the same
JP3450080B2 (en) * 1995-02-01 2003-09-22 有限会社野々川商事 Health foods and pharmaceuticals containing procyanidin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672800A1 (en) * 1991-02-15 1992-08-21 Dolisos Lab NOVEL THERAPEUTIC USE OF PYCNOGENOLS FOR THE PREPARATION OF MEDICAMENTS WITH ANTI-INFLAMMATORY ACTIVITY.
WO1993024106A1 (en) * 1992-05-27 1993-12-09 L'oreal Composition comprising a proanthocyanidin oligomer encapsulated in a liposome
EP0815857A1 (en) * 1995-12-26 1998-01-07 Suntory Limited Antiobestic agent containing procyanidin as the active ingredient
FR2770228A1 (en) * 1997-10-27 1999-04-30 Greentech Sa Proanthocyanidine oligomer concentrates obtained by fermenting Schinopsis lorenzii extract

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, LEE EUN BANG ET AL: "The influence of methanol extract of Ulmus davidiana var. Japonica cortex on gastric erosion and ulcer and paw edema in rats.", XP002235805, Database accession no. PREV199698732403 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1994, EUN J S ET AL: "The combined effects of n-BuOH fraction of Ulmi Cortex and anticancer drugs on cancer cell lines", XP002235806, Database accession no. EMB-1994193448 *
GALI H V ET AL: "COMPARISON OF THE INHBITORY EFFECTS OF MONOMERIC, DIMERIC, AND TRIMERIC PROCYANIDINS ON THE BIOCHEMICAL MARKERS OF SKIN TUMOR PROMOTION IN MOUSE EPIDERMIS IN VIVO", PLANTA MEDICA, THIEME, STUTTGART, DE, vol. 60, no. 3, June 1994 (1994-06-01), pages 235 - 239, XP001088243, ISSN: 0032-0943 *
JUN CHANG-DUK ET AL: "Inhibition of nitric oxide synthesis by butanol fraction of the methanol extract of Ulmus davidiana in murine macophages.", JOURNAL OF ETHNOPHARMACOLOGY, vol. 62, no. 2, 1998, pages 129 - 135, XP002235804, ISSN: 0378-8741 *
KOREAN JOURNAL OF PHARMACOGNOSY 1994 SOUTH KOREA, vol. 25, no. 2, 1994, pages 144 - 152, ISSN: 0253-3073 *
MAFFEI FACINO R ET AL: "Free radicals scavenging action and anti-enzyme activities of procyanidine from Vitis vinifera: A mechanism for their capillary protective action.", ARZNEIMITTEL-FORSCHUNG, vol. 44, no. 5, 1994, pages 592 - 601, XP001146733, ISSN: 0004-4172 *
See also references of WO0105397A1 *
YAKHAK HOEJI, vol. 39, no. 6, 1995, pages 671 - 675, ISSN: 0513-4234 *

Also Published As

Publication number Publication date
CA2379489A1 (en) 2001-01-25
KR20010010154A (en) 2001-02-05
WO2001005397A1 (en) 2001-01-25
KR100509119B1 (en) 2005-08-18
MXPA02000598A (en) 2003-07-21
JP2003504402A (en) 2003-02-04
BR0012431A (en) 2002-09-24
WO2001005397A8 (en) 2001-04-05
CN1364082A (en) 2002-08-14
EP1196162A1 (en) 2002-04-17
AU5713000A (en) 2001-02-05

Similar Documents

Publication Publication Date Title
EP1196162A4 (en) Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same
IL148630A0 (en) Compounds and pharmaceutical compositions for inhibiting cathepsin s
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
PL352282A1 (en) Derivatives of thiazoles and pharmaceutical compositions containing these derivatives
PL354168A1 (en) Pharmaceutical composition of nateglinide and another antidiabetcagent
HUP0202897A3 (en) Diaminothiazoles and their use for inhibiting protein kinases and pharmaceutical compositions containing them
HUP0200831A3 (en) Novel pharmaceutical composition containing amoxycillin and its use
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
HUP0201214A3 (en) Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use
HUP0104316A3 (en) Substituted benzopyran analogs for the treatment of inflammation and pharmaceutical compositions containing them
HUP0201334A3 (en) Hydrochloride of fused-heterocycle compound and pharmaceutical compositions containing the same
ZA987800B (en) Pharmaceutical composition of meloxicam
ATE263558T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LIPASE INHIBITORS AND CHITOSAN
HUP0103575A3 (en) Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use
HUP0103874A3 (en) Use of antibiotics and pharmaceutical compositions comprising thereof
IL144592A0 (en) Heterocyclic aromatic compounds and pharmaceutical compositions containing the same
HUP0200588A2 (en) Diaryl derivatives and pharmaceutical compositions containing them and their use
HUP0102714A3 (en) Tricyclic sulfonamid derivatives as inhibitors of matrix metalloproteinases and medicaments containing the same
HUP0102255A3 (en) Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
AU7327298A (en) Use of a pharmaceutical composition for treating and/or preventing ischemia
HUP0105160A3 (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-betha-cyclodextrin or 2-hydroxypropyl-betha-cyclodextrin and method for its preparation and pharmaceutical compositions containing them
HUP0105204A3 (en) Substituted phenethylamine derivatives and pharmaceutical compositions containing them
HUP0201846A2 (en) Amonobenzophenones as inhibitors of il-1betha and tnf-alpha and pharmaceutical compositions containing them
HUP0201714A3 (en) Substituted heterocyclic compounds and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LG HOUSEHOLD & HEALTH CARE LTD.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 35/78 B

Ipc: 7A 61K 31/35 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030508

17Q First examination report despatched

Effective date: 20030916

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050611